# US 2024/0201168 A1 · Composition for diagnosis or treatment of anticancer drug resistance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201168 A1
- Document ID: US20240201168A1
- Status: Published application
- Kind: A1
- Application number: 17/905,491
- Filed: 2021-03-02
- Published: 2024-06-20
- Earliest claimed: 2020-03-02
- Assignees: Jong-Baeck Lim
- Inventors: Jong-Baeck Lim; Jae-Il Choi; Hye Won Chung
- Web page: https://patentgrep.com/patent/US20240201168A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5023: {on expression patterns}
- G01N 33/575: for cancer
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12N 2310/11: Antisense
- G01N 2333/70585: CD44
- G01N 2800/44: Multiple drug resistance
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a composition for diagnosing resistance to a combination of ECF (Epirubicin, Cisplatin and 5-Fluorouracil; ECF), which is used for the treatment of gastric cancer, and a diagnostic kit comprising the same. In order to solve a problem that cancer recurrence and drug resistance occur due to an increase in tumor initiating cells (TICs) after treatment with a drug belonging to the ECF family, NINJ2 may be inhibited by early detection of resistance appearance, thereby suppressing the recurrence of gastric cancer and treating resistance to the drugs.

## Claims

### Claim 1

A method for diagnosing anticancer drug resistance, comprising measuring an expression level of NINJ2 (nerve injury-induced protein 2; Ninjurin 2) protein or a gene encoding the protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the measuring of the expression level of the protein is carried out using at least one selected from the group consisting of an antibody, an oligopeptide, a ligand, a peptide nucleic acid (PNA), and an aptamer, which bind specifically to the protein.

### Claim 3 (depends on 1)

The method of claim 1, wherein the measuring of the expression level of the gene is carried out using at least one selected from the group consisting of a primer, a probe, and an antisense nucleotide, which bind specifically to the gene.

### Claim 4 (depends on 1)

The method of claim 1, wherein the anticancer drug comprises at least one selected from the group consisting of nitrogen mustard, imatinib, oxaliplatin, rituximab, erlotinib, neratinib, lapatinib, gefitinib, vandetanib, nirotinib, semasanib, bosutinib, axitinib, cediranib, lestaurtinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, bevacizumab, cisplatin, cetuximab, viscumalbum, asparaginase, tretinoin, hydroxycarbamide, dasatinib, estramustine, gemtuzumab ozogamicin, ibritumomab tusetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab, procarbazine, alprostadil, holmium nitrate chitosan, gemcitabine, doxyfluridine, pemetrexed, tegafur, capecitabine, gimeracin, oteracil, azacitidine, methotrexate, uracil, cytarabine, fluorouracil, fludagabine, enocitabine, flutamide, decitabine, mercaptopurine, thioguanine, cladribine, carmofur, raltitrexed, docetaxel, paclitaxel, irinotecan, belotecan, topotecan, vinorelbine, etoposide, vincristine, vinblastine, teniposide, doxorubicin, idarubicin, epirubicin, mitoxantrone, mitomycin, bleomycin, daunorubicin, dactinomycin, pirarubicin, aclarubicin, peplomycin, temsirolimus, temozolomide, busulfan, ifosfamide, cyclophosphamide, melphalan, altretamine, dacarbazine, thiotepa, nimustine, chlorambucil, mitolactol, leucovorin, tretonine, exemestane, aminoglutethimide, anagrelide, navelbine, fadrazol, tamoxifen, toremifen, testolactone, anastrozole, letrozole, vorozole, bicalutamide, lomustine, and carmustine.

### Claim 5 (depends on 4)

The method of claim 4, wherein the anticancer drug comprises any one or more selected from the group consisting of epirubicin, cisplatin and 5-fluorouracil.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anticancer drug is for treatment of cancer which is thyroid cancer, parathyroid cancer, gastric cancer, ovarian cancer, colorectal cancer, pancreatic cancer, liver cancer, breast cancer, cervical cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, biliary tract cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, blood cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head cancer, uterine cancer, rectal cancer, brain tumor, perianal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine cancer, endocrine adenocarcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, ureter cancer, renal cell carcinoma, renal pelvic carcinoma, CNS central nervous system tumor, primary CNS lymphoma, spinal cord tumor, brainstem glioma, or pituitary adenoma.

### Claim at position 7

7-12. (canceled)

### Claim 13

A method for preventing or treating cancer, comprising a step of administering an effective amount of an agent to a subject in need thereof, wherein the agent is for reducing an activity or expression level of NINJ2 (nerve injury-induced protein 2; Ninjurin 2) protein, or an agent for reducing an expression level of a gene encoding the protein.

### Claim 14 (depends on 13)

The method of claim 13, wherein the agent for reducing the activity or expression level of the protein is any one or more selected from the group consisting of compounds, peptides, peptide mimetics, aptamers, antibodies, and natural products, which bind specifically to the NINJ2 protein or a portion thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein the agent for reducing the expression level of the gene is any one or more selected from the group consisting of an antisense nucleotide, a short interfering RNA (siRNA), a short hairpin RNA, and ribozyme, which bind complementarily to the NINJ2 gene or a portion thereof.

### Claim 16 (depends on 13)

The method of claim 13, wherein the cancer is thyroid cancer, parathyroid cancer, gastric cancer, ovarian cancer, colorectal cancer, pancreatic cancer, liver cancer, breast cancer, cervical cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, biliary tract cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, blood cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head cancer, uterine cancer, rectal cancer, brain tumor, perianal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine cancer, endocrine adenocarcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, ureter cancer, renal cell carcinoma, renal pelvic carcinoma, CNS central nervous system tumor, primary CNS lymphoma, spinal cord tumor, brainstem glioma, or pituitary adenoma.

### Claim 17

(canceled)

### Claim 18

A method for treating anticancer drug resistance or enhancing anticancer drug sensitivity, comprising a step of administering an effective amount of an agent to a subject in need thereof, wherein the agent is for reducing an activity or expression level of NINJ2 (nerve injury-induced protein 2; Ninjurin 2) protein, or an agent for reducing an expression level of a gene encoding the protein.

### Claim 19 (depends on 18)

The method of claim 18, wherein the agent for reducing the activity or expression level of the protein is any one or more selected from the group consisting of compounds, peptides, peptide mimetics, aptamers, antibodies, and natural products, which bind specifically to the NINJ2 protein or a portion thereof.

### Claim 20 (depends on 18)

The method of claim 18, wherein the agent for reducing the expression level of the gene is any one or more selected from the group consisting of an antisense nucleotide, a short interfering RNA (siRNA), a short hairpin RNA, and ribozyme, which bind complementarily to the NINJ2 gene or a portion thereof.

### Claim 21 (depends on 18)

The method of claim 18, wherein the anticancer drug comprises at least one selected from the group consisting of nitrogen mustard, imatinib, oxaliplatin, rituximab, erlotinib, neratinib, lapatinib, gefitinib, vandetanib, nirotinib, semasanib, bosutinib, axitinib, cediranib, lestaurtinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, bevacizumab, cisplatin, cetuximab, viscumalbum, asparaginase, tretinoin, hydroxycarbamide, dasatinib, estramustine, gemtuzumab ozogamicin, ibritumomab tusetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab, procarbazine, alprostadil, holmium nitrate chitosan, gemcitabine, doxyfluridine, pemetrexed, tegafur, capecitabine, gimeracin, oteracil, azacitidine, methotrexate, uracil, cytarabine, fluorouracil, fludagabine, enocitabine, flutamide, decitabine, mercaptopurine, thioguanine, cladribine, carmofur, raltitrexed, docetaxel, paclitaxel, irinotecan, belotecan, topotecan, vinorelbine, etoposide, vincristine, vinblastine, teniposide, doxorubicin, idarubicin, epirubicin, mitoxantrone, mitomycin, bleomycin, daunorubicin, dactinomycin, pirarubicin, aclarubicin, peplomycin, temsirolimus, temozolomide, busulfan, ifosfamide, cyclophosphamide, melphalan, altretamine, dacarbazine, thiotepa, nimustine, chlorambucil, mitolactol, leucovorin, tretonine, exemestane, aminoglutethimide, anagrelide, navelbine, fadrazol, tamoxifen, toremifen, testolactone, anastrozole, letrozole, vorozole, bicalutamide, lomustine, and carmustine.

### Claim at position 17

22-28. (canceled)

### Claim 28

A method for screening a drug for treating anticancer drug resistance, comprising:
treating cancer cells expressing NINJ2 (nerve injury-induced protein 2; Ninjurin 2) protein or a gene encoding the protein, or an anticancer drug-resistant cancer organoid comprising cancer cells expressing NINJ2 (nerve injury-induced protein 2; Ninjurin 2) protein or a gene encoding the protein, with a candidate substance in vitro; and
measuring an activity or expression level of the NINJ2 protein or an expression level of the gene encoding the protein in the cancer cells or the cancer organoid after treatment with the candidate substance.

### Claim 29 (depends on 28)

The method of claim 28, further comprising a step of measuring an activity or expression level of at least one protein selected from among CD44 and periostin proteins, or measuring an expression level of a gene encoding at least one protein.

### Claim 30 (depends on 28)

The method of claim 28, further comprising a step of determining that the candidate substance is the drug for treating anticancer drug resistance, when the measured activity or expression level of the NINJ2 protein decreases after treatment with the candidate substance, or the measured expression level of the gene encoding the protein decreases after treatment with the candidate substance.

### Claim at position 21

31-36. (canceled)
